Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may spot diabetes risk after pregnancy

NCT ID NCT02133729

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 255 women with gestational diabetes to see if simple blood tests during pregnancy could predict who will develop type 2 diabetes after giving birth. Researchers measured three markers (CRP, MDA, and adiponectin) and checked glucose tolerance three months after delivery. The goal is to focus follow-up care on women at highest risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which women with gestational diabetes are at highest risk for type 2 diabetes, allowing earlier prevention efforts.
What could go wrong
This is an observational study, not a treatment trial. The markers tested may not prove accurate enough for routine use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

255 people

The number who actually took part.

Start date

Jun 2011

Finished

Apr 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged over 18years old * Women with the criteria of GDM during pregnancy at 21-35 weeks of gestation (one situation): * After a 75g Oral Glucose Tolerance Test (OGTT - WHO criteria) with blood glucose (BG) values at T60≥180mg/dl and/or T120≥153mg/dl * An O. Sullivan test following a 100g oral glucose load with at least two pathological values (T60 ≥ 180mg/dl and/or T120 ≥ 155mg/dl and/or T180 ≥ 140mg/dl) * With a fasting BG value ≥92mg/dl * Women with signed informed consent Exclusion Criteria: * Women aged less than 18years old * Women with pregestational type 2 diabetes * Women without signed informed consent * Women who does not read and/or understand french language * Women not affiliated to the health care system * Women with recent infection (\<1month) and/or on steroids or anti-inflammatory drugs. * Women with chronic diseases * Women with a disable state * Women with normal glucose tolerance * Women already incorporated in another clinical study that could interfere with the present study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gestational diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational diabetes

Contacts and locations

Locations

  • CHU Clermont-Ferrand - Hôpital Gabriel Montpied - Service d'endocrinologie

    Clermont-Ferrand, 63003, France

  • CHU Grenoble - Clinique d'Endocrinologie Diabétologie Nutrition

    Grenoble, 38000, France

  • CHU Saint Etienne - Hôpital Nord - Service d'endocrinologie, diabètes, nutrition

    Saint-Etienne, 42055, France

  • Centre Hospitalier de Givors - Hôpital de Montgelas - Service de médicine 8

    Givors, 69700, France

  • Groupement Hospitalier des Portes du Sud - Service d'Endocrinologie Diabétologie Nutrition

    Vénissieux, 69200, France

  • Hospices Civils de Lyon - Groupement Hospitalier Sud - Service d'Endocrinologie, Diabète, Nutrition

    Pierre-Bénite, 69495, France

  • Hospices Civils de Lyon - Hôpital Femme-Mère-Enfant - Service de gynécologie obstétrique

    Bron, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.